Indian pharma majors rally for strong US-India trade alliance

As the Indian pharmaceutical industry is propelled by government initiatives to transition from its traditional focus on generic drug production to the development of high-value, innovative products, domestic pharma majors are advocating for a robust US-India trade partnership.

Drug producers emphasize that India's substantial contributions, particularly its supply of 47% of all generic prescriptions in the USA, highlight the critical need and significance of this bilateral collaboration, reports The Pharma Letter’s India correspondent.

At a recent gathering convened by the Indian Pharmaceutical Alliance (IPA) at the DAR Museum in Washington DC, speakers underscored how Indian generics are key players in the US market.